Carbatrol.com: Register for Exclusive Offers

For the treatement of partial and generalized seizures

With Carbatrol, the most frequently observed adverse reactions, particularly during the initial phases of therapy, were dizziness, drowsiness, unsteadiness, nausea, and vomiting.

Patients & Caregivers

Health Care Professionals

Shire is pleased to provide the following educational materials on epilepsy. You and your staff can use the following tools to help your patients understand the challenges of epilepsy. Simply select the exclusive offers that interest you and click Submit.

	Download a Carbatrol Resource Pack: (zip file) View a resource to help your patients learn more about epilepsy, how Carbatrol works and the particular challenges women and children with the disease may face. The Resource Pack includes an informative brochure, details ways to manage the uncertainties your patients may come across and how Carbatrol may help control seizures.
	Request a "Taking Control of Epilepsy" DVD: (Free—mailed to your physical address.) An informative and inspiring half-hour TV documentary for patients and their caregivers. The DVD includes interviews with leading epileptologists and profiles of everyday people living with epilepsy. The focus is on how these patients deal with their seizure disorder, treatment options they pursue and how epilepsy fits into their lives as a whole. Originally aired in September 2002, the program was produced by Healthy Solutions and sponsored by Shire US Inc., the maker of Carbatrol.
	I acknowledge that I am 13 years of age or older. Yes No

Anticonvulsants should be taken in the manner and at the times prescribed by the physician.

Important Safety Information for Health Care Professionals

Carbatrol^® contains carbamazepine. Please ensure patient is not taking any other form of carbamazepine.
The most frequently observed adverse reactions, particularly during the initial phases of therapy, are dizziness, drowsiness, unsteadiness, nausea, and vomiting. Initiating therapy at the lowest possible effective dose can minimize adverse reactions.
Toxic epidermal necrolysis and Stevens-Johnson syndrome have been reported with use of carbamazepine. These skin disorders are rare, but appear to be more common in patients of Asian ancestry. A strong association between Asian ancestry and the presence of HLA-B*1502 allele in the development of toxic epidermal necrolysis and Stevens-Johnson syndrome has been reported. Patients of ancestry in genetically at-risk populations should be screened for the presence of HLA-B*1502 prior to initiating Carbatrol. Patients testing positive for the allele should not be treated with Carbatrol unless the benefit clearly outweighs the risk.
Aplastic anemia and agranulocytosis have been reported in association with the use of carbamazepine. Reports of transient or persistent decreased platelet or white blood cell counts are not uncommon in association with the use of carbamazepine. However, the vast majority of the cases of leukopenia have not progressed to the more serious conditions of aplastic anemia or agranulocytosis. Nonetheless, complete pretreatment hematological testing should be obtained as a baseline. If a patient in the course of treatment exhibits low or decreased white blood cell or platelet counts, the patient should be monitored closely. Discontinuation of the drug should be considered if any evidence of significant bone marrow depression develops.
Carbamazepine should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug, or known sensitivity to any of the tricyclic compounds.
Carbamazepine is Pregnancy Category D.
Absence seizures (petit mal) do not appear to be controlled by carbamazepine.

See Important Safety Information for Health Care Professionals

This site is strictly intended for US residents and is governed solely by US laws and governmental regulations. Please see our online privacy policy for more information.

While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on the site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of the site.

Carbatrol^® is registered in the United States Patent and Trademark Office.
Tegretol^® is a registered trademark of Novartis Pharmaceuticals Corporation.
Depakote^® is a registered trademark of Abbott Laboratories.
Microtrol^® is registered in the United States Patent and Trademark Office.